TABLE 1.
Baseline characteristics and exposure variables for the hypogamma‐MS cohort.
| Stockholm | Northern region | Gothenburg | Overall | |
|---|---|---|---|---|
| (N = 1870) | (N = 458) | (N = 417) | (N = 2745) | |
| Sex | ||||
| Female | 1550 (82.9%) | 310 (67.7%) | 274 (65.7%) | 2134 (77.7%) |
| Male | 320 (17.1%) | 148 (32.3%) | 143 (34.3%) | 611 (22.3%) |
| Age | ||||
| Mean (SD) | 42.0 (11.4) | 41.0 (11.5) | 43.7 (12.3) | 42.1 (11.6) |
| Median (min, max) | 41.9 (14.4, 77.8) | 41.6 (13.5, 75.1) | 43.0 (9.73, 74.6) | 42.1 (9.73, 77.8) |
| MS subtype | ||||
| RRMS | 1397 (74.7%) | 355 (77.5%) | 288 (69.1%) | 2040 (74.3%) |
| SPMS | 383 (20.5%) | 74 (16.2%) | 92 (22.1%) | 549 (20.0%) |
| PPMS | 75 (4.0%) | 29 (6.3%) | 37 (8.9%) | 141 (5.1%) |
| NA | 15 (0.8%) | 0 (0%) | 0 (0%) | 15 (0.5%) |
| EDSS | ||||
| Mean (SD) | 2.88 (2.06) | 2.58 (1.95) | 3.70 (2.19) | 2.96 (2.09) |
| Median (min, max) | 2.50 (0, 9.00) | 2.00 (0, 9.00) | 3.00 (1.00, 9.00) | 2.50 (0, 9.00) |
| Missing | 219 (11.7%) | 55 (12.0%) | 39 (9.4%) | 313 (11.4%) |
| Previous DMT | ||||
| Treatment‐naïve | 577 (30.9%) | 178 (38.9%) | 123 (29.5%) | 878 (32.0%) |
| Natalizumab | 361 (19.3%) | 89 (19.4%) | 135 (32.4%) | 585 (21.3%) |
| Interferon β | 375 (20.1%) | 117 (25.5%) | 45 (10.8%) | 537 (19.6%) |
| Dimethyl fumarate | 211 (11.3%) | 8 (1.7%) | 39 (9.4%) | 258 (9.4%) |
| Fingolimod | 187 (10.0%) | 21 (4.6%) | 26 (6.2%) | 234 (8.5%) |
| Glatiramer acetate | 76 (4.1%) | 21 (4.6%) | 12 (2.9%) | 109 (4.0%) |
| Other | 47 (2.5%) | 23 (5.0%) | 24 (5.8%) | 94 (3.4%) |
| Teriflunomide | 36 (1.9%) | 1 (0.2%) | 13 (3.1%) | 50 (1.8%) |
| IgG | ||||
| Mean (SD) | 10.5 (2.28) | 10.6 (2.23) | 10.2 (2.22) | 10.5 (2.27) |
| Median (min, max) | 10.3 (1.50, 20.9) | 10.4 (5.70, 18.8) | 10.0 (4.40, 16.0) | 10.3 (1.50, 20.9) |
| Missing | 314 (16.8%) | 296 (64.6%) | 230 (55.2%) | 840 (30.6%) |
| IgM | ||||
| Mean (SD) | 1.10 (0.635) | 1.05 (0.595) | 1.10 (0.761) | 1.10 (0.635) |
| Median (min, max) | 0.97 (0, 5.15) | 0.99 (0.14, 3.2) | 0.85 (0.26, 3.7) | 0.97 (0, 5.15) |
| Missing | 372 (19.9%) | 390 (85.2%) | 397 (95.2%) | 1159 (42.2%) |
| Time diagnosis to RTX start (years) | ||||
| Mean (SD) | 7.00 (7.28) | 5.50 (6.28) | 7.73 (7.22) | 6.85 (7.14) |
| Median (min, max) | 4.84 (−1.76, 43.1) | 3.43 (−0.397, 31.0) | 6.20 (−1.27, 35.1) | 4.74 (−1.76, 43.1) |
| Missing | 53 (2.8%) | 4 (0.9%) | 20 (4.8%) | 77 (2.8%) |
| Time from diagnosis to RTX start (years) | ||||
| Mean (SD) | 7.00 (7.28) | 5.50 (6.28) | 7.73 (7.22) | 6.85 (7.14) |
| Median (min, max) | 4.84 (−1.76, 43.1) | 3.43 (−0.397, 31.0) | 6.20 (−1.27, 35.1) | 4.74 (−1.76, 43.1) |
| Missing | 53 (2.8%) | 4 (0.9%) | 20 (4.8%) | 77 (2.8%) |
| Time on RTX treatment | ||||
| Mean (SD) | 1010 (664) | 1700 (865) | 1070 (715) | 1130 (753) |
| Median (min, max) | 984 (0, 3150) | 1690 (0, 4170) | 978 (0, 4320) | 1100 (0, 4320) |
| Received doses of RTX | ||||
| Mean (SD) | 5.90 (3.16) | 7.35 (2.76) | 6.25 (3.35) | 6.19 (3.17) |
| Median (min, max) | 6.00 (1.00, 25.0) | 8.00 (1.00, 28.0) | 6.00 (1.00, 22.0) | 6.00 (1.00, 28.0) |
| Accumulated dose of RTX | ||||
| Mean (SD) | 3240 (1870) | 5720 (2550) | 4430 (2730) | 3830 (2340) |
| Median (min, max) | 3000 (500, 12,600) | 5900 (500, 15,000) | 3500 (1000, 19,500) | 3500 (500, 19,500) |
Abbreviations: DMT, disease‐modifying therapy; EDSS, Expanded Disability Status Scale; IgG, immunoglobulin G; IgM, immunoglobulin M; MS, multiple sclerosis; NA, Not Available; PPMS, primary progressive multiple sclerosis; RRMS, relapsing–remitting multiple sclerosis; RTX, rituximab; SPMS, secondary progressive multiple sclerosis.